Gennex Laboratories Stock Screener | Share Price & Fundamental Analysis
GENNEX
Pharmaceuticals
Screen Gennex Laboratories share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price BSE
₹13.58
▼
-0.27 (-1.95%)
Market Cap
₹328.73 Cr.
P/E Ratio (TTM)
17.99
P/B Ratio
1.58
EPS (TTM)
₹0.80
Dividend Yield
-
Debt to Equity
0.04
52W High
₹17.02
52W Low
₹11.24
Operating Margin
15.00%
Profit Margin
15.38%
Revenue (TTM)
₹39.00
EBITDA
₹8.00
Net Income
₹6.00
Total Assets
₹256.00
Total Equity
₹195.00
Gennex Laboratories Share Price History - Stock Screener Chart
Screen GENNEX historical share price movements with interactive charts. Analyze price trends and patterns.
Gennex Laboratories Company Profile - Fundamental Screener
Screen Gennex Laboratories company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for GENNEX shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE509C01026
Gennex Laboratories Balance Sheet Screener - Fundamental Analysis
Fair Value AnalysisScreen GENNEX balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Total Assets | 256 | 230 | 132 | 68 | 59 | 57 | 52 | 51 | 49 |
| Current Assets | 181 | 162 | 49 | 47 | 38 | 35 | 29 | 28 | 26 |
| Fixed Assets | 60 | 56 | 74 | 14 | 14 | 15 | 16 | 16 | 16 |
| Liabilities | |||||||||
| Total Liabilities | 256 | 230 | 132 | 68 | 59 | 57 | 52 | 51 | 49 |
| Current Liabilities | 17 | 13 | 16 | 0 | 0 | 0 | 1 | 1 | 1 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | |||||||||
| Total Equity | 195 | 177 | 87 | 44 | 40 | 36 | 34 | 32 | 31 |
| Share Capital | 23 | 23 | 18 | 13 | 13 | 13 | 13 | 13 | 13 |
| Reserves & Surplus | 158 | 142 | 62 | 31 | 27 | 23 | 21 | 19 | 18 |
Screen GENNEX income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
| Item | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Mar | 2022-Dec | 2022-Sept | 2022-Jun | 2022-Mar |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 39 | 37 | 44 | 38 | 32 | 31 | 34 | 19 | 18 | 17 | 19 | 14 | 19 | 14 | 20 |
| Expenses | 32 | 29 | 39 | 33 | 26 | 24 | 29 | 17 | 12 | 11 | 17 | 13 | 18 | 13 | 19 |
| EBITDA | 8 | 7 | 6 | 5 | 6 | 7 | 4 | 3 | 5 | 5 | 1 | 1 | 1 | 1 | 1 |
| Operating Profit % | 15.00% | 15.00% | 5.00% | 13.00% | 18.00% | 15.00% | 13.00% | 13.00% | 29.00% | 31.00% | 7.00% | 8.00% | 7.00% | 6.00% | 4.00% |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Interest | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 6 | 6 | 4 | 6 | 6 | 6 | 5 | 4 | 4 | 4 | 3 | 2 | 1 | 1 | 1 |
| Tax | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Net Profit | 6 | 5 | 3 | 5 | 5 | 5 | 5 | 3 | 3 | 3 | 2 | 1 | 1 | 1 | 1 |
| EPS | 0.21 | 0.22 | 0.14 | 0.22 | 0.21 | 0.19 | 0.16 | 0.16 | 0.16 | 0.16 | 0.19 | 0.07 | 0.08 | 0.06 | 0.10 |
Gennex Laboratories Cash Flow Screener - Liquidity Fundamentals
Screen GENNEX cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March |
|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | -11 | -47 | 24 | 12 | -1 | -2 | 2 | 3 | 0 |
| Investing Activities | 1 | 19 | -38 | -3 | 0 | 0 | -1 | -1 | -1 |
| Financing Activities | 5 | 74 | 21 | -2 | 2 | 0 | 1 | -2 | 1 |
| Net Cash Flow | -5 | 46 | 6 | 8 | 0 | -2 | 2 | 0 | 0 |
Screen GENNEX shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
| Item | 2025-Mar | 2025-Jun | 2025-Jul | 2025-Sept | 2024-Feb | 2024-Mar | 2024-Jun | 2024-Sept |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 18.42% | 19.83% | 23.62% | 23.62% | 18.42% | 18.42% | 18.42% | 18.42% |
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 62.19% | 61.90% | 58.97% | 59.34% | 58.81% | 60.42% | 61.74% | 59.00% |
| Other Holding | 19.39% | 18.28% | 17.41% | 17.04% | 22.78% | 21.16% | 19.85% | 22.59% |
| Shareholder Count | 92,326 | 91,183 | 91,183 | 90,320 | 69,750 | 83,996 | 87,820 | 90,236 |
Gennex Laboratories Dividend Screener - Share Yield Analysis
Screen GENNEX dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
Gennex Laboratories Index Membership - Market Screener Classification
Screen GENNEX by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
Gennex Laboratories Market Events Screener - Corporate Actions
Screen GENNEX market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Annual General Meeting | NA | 27.26% | ||
| Annual General Meeting | NA | -0.44% | ||
| 2025-11-14 | 2025-11-14 | Quarterly Result Announcement | NA | 1.36% |
| 2025-08-14 | 2025-08-14 | Quarterly Result Announcement | NA | -4.23% |
| 2025-05-30 | 2025-05-30 | Quarterly Result Announcement | NA | 5.19% |
| 2025-02-14 | 2025-02-14 | Quarterly Result Announcement | NA | -6.70% |
| 2024-11-14 | 2024-11-14 | Quarterly Result Announcement | NA | -5.88% |
| 2023-12-30 | 2023-12-30 | Extraordinary General Meeting | NA | 4.41% |
| 2022-07-21 | 2022-07-22 | Rights | 1:2 | 2.40% |
Gennex Laboratories Competitors Screener - Peer Comparison
Screen GENNEX competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 427,705 | 40.28 | 54,729 | 9.71% | 10,980 | 58.99 |
| Divis Laboratories | 176,338 | 70.98 | 9,712 | 18.67% | 2,191 | 63.15 |
| Torrent Pharmaceuticals | 138,499 | 62.26 | 11,539 | 6.99% | 1,911 | 80.95 |
| Cipla | 118,573 | 22.75 | 28,410 | 7.12% | 5,291 | 38.52 |
| Dr Reddys Laboratories | 103,728 | 18.27 | 33,741 | 16.73% | 5,725 | 40.17 |
| Lupin | 101,149 | 22.61 | 22,910 | 13.74% | 3,306 | 71.67 |
| Mankind Pharma | 95,432 | 52.17 | 12,744 | 20.90% | 2,007 | 64.16 |
| Zydus Life Science | 93,333 | 18.63 | 23,511 | 18.55% | 4,615 | 52.14 |
| Aurobindo Pharma | 71,752 | 20.91 | 32,346 | 9.43% | 3,484 | 61.25 |
| Alkem Laboratories | 69,425 | 28.04 | 13,458 | 3.70% | 2,216 | 63.97 |
Gennex Laboratories Company Announcements - News Screener
Screen GENNEX latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2025-12-16 | Closure of Trading Window | View |
| 2025-11-17 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-11-14 | Unaudited Financial Results For The Quarter And Half Year Ended September 30 2025 | View |
| 2025-11-14 | Board Meeting Outcome for Unaudited Financial Results For The Quarter And Half Year Ended September 30 2025 | View |
| 2025-11-06 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-11-04 | Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results (Standalone And Consolidated) For The Quarter And Half Year Ended September 30 2025 | View |
| 2025-10-13 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | View |
| 2025-10-01 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | View |
| 2025-09-30 | Shareholder Meeting / Postal Ballot-Outcome of AGM | View |
| 2025-09-23 | Closure of Trading Window | View |
| 2025-09-08 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-09-08 | Reg. 34 (1) Annual Report. | View |
| 2025-09-04 | Intimation Of Book Closure For AGM | View |
| 2025-09-04 | Board Meeting Outcome for For Meeting Held On 04Th September 2025 For Approval Of Board Reports And AGM Related Agenda | View |
| 2025-08-26 | Board Meeting Intimation for Fixing Date Time And Venue Of 40Th AGM Of The Company | View |
| 2025-08-18 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-08-14 | Unaudited Financial Results For The Quarter Ended June 30 2025 | View |
| 2025-08-14 | Board Meeting Outcome for Outcome Of The Board Meeting Of Gennex Laboratories Limited Held On August 14 2025 For Unaudited Financial Results Of First Quarter Ended June 30 2025 | View |
| 2025-08-07 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-07-28 | Approval Of Products From Drugs Control Administration Government Of Andhra Pradesh For Our Subsidiary Company Deccan Remedies Limited | View |